Regulating Pharmaceutical Prices in India

Based on rigorous analysis of comprehensive time-series data on the industry
Written for administrators, policy makers, as well as researchers dealing with regulation and pharma industry
Presents ways to improve pharmaceutical price controls

Based on rigorous analysis of comprehensive time-series data on the industry Written for administrators, policy makers, as well as researchers dealing with regulation and pharma industry Presents ways to improve pharmaceutical price controls

Autorentext

Ajay Bhaskarabhatla is an associate professor at Erasmus School of Economics, The Netherlands. Ajay's research on the Indian pharmaceutical industry has been published in top peer-reviewed journals.

Inhalt

Introduction.- Part I. Historical Context and the Motivation for Regulation.- Brief History of Regulating Pharmaceutical Prices.- Is the 2013 Price Control Regulation Necessary?.- Part II. The Design of the 2013 DPCO Regulation.- The Proposed Design to Fix Ceiling Prices Under 2013 DPCO.- Challenges with Fixing the Ceiling Price Under the 2013 DPCO.- Part III. The Impact of the 2013 DPCO.- How Effective Are the 2013 DPCO Regulations?.- Firm Strategies to Mitigate the Impact of Price Control Regulation.- Part IV. Enforcement and Compliance.- Enforcement and Compliance with Price Ceilings on Essential Medicines.- Conclusion.